It is estimated that about 10% of patients who have been infected with
SARS-CoV-2 worldwide suffer from Long-Covid, about 65 million people
. Although we are beginning to know its pathophysiology, there is
still no evidence on its treatment. We present the case of a patient
with persistent prolonged symptoms who had an optimal response to
nirmatrelvir/ritonavir 2 years after acute infection.